Showing results (1-10 of 283) with videos related to
Sort By:
Pageof 29
Cancer Chemotherapy and Pharmacology|January 27, 2000
Four-hourly scheduling of temozolomide improves tumour growth delay but not therapeutic index in A375M melanoma xenograftsM R Middleton, J Kelly, S Goodger, et al.International Journal of Cancer|October 31, 2000
O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II studyM R Middleton, S M Lee, A Arance, et al.British Journal of Cancer|March 29, 2000
A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanomaM R Middleton, P Lorigan, J Owen, et al.Melanoma Research|April 4, 2002
Effect of temozolomide on central nervous system relapse in patients with advanced melanomaM J Paul, Y Summers, A H Calvert, et al.Lung Cancer (Amsterdam, Netherlands)|March 1, 1994
Treatment evaluation of combined modality therapy: 'what can we obtain today from phase II trials?'N ThatcherCurrent Opinion in Oncology|April 1, 1991
Recombinant interleukin-2 and other types of treatment of advanced malignant melanomaN ThatcherLung Cancer (Amsterdam, Netherlands)|November 27, 2001
Chemotherapy for advanced non-small cell lung cancerN ThatcherSeminars in Oncology|July 22, 1998
Management of chemotherapy-induced anemia in solid tumorsN ThatcherJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2003
Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanomaS Danson, P Lorigan, A Arance, et al.International Journal of Cancer|January 11, 2000
O(6)-(4-bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenograftsM R Middleton, J Kelly, N Thatcher, et al.Pageof 29